COVID associated mucormycosis: various trends, effects of treatment and sequelae
DOI:
https://doi.org/10.18203/issn.2454-5929.ijohns20232518Keywords:
COVID associated mucormycosis, Surgical debridement, CAM, Fungal sinusitisAbstract
Background: With second wave of covid-19 pandemic rapid rise in cases of covid associated mucormycosis (CAM) was detected. The primary reason that appears to be facilitating Mucorales spores to germinate in people with COVID-19 is an ideal environment of low oxygen, high blood glucose, acidic medium (metabolic acidosis, diabetic ketoacidosis [DKA], high serum iron levels. Aim of this study is to evaluate the extent of disease, its causative factors, various associations and effect of treatment.
Methods: This is a prospective study done on 180 patients. Detailed history and diagnostic nasal endoscopic guided biopsies were taken and sent for histopathological and microbial examination. Computed tomography (CT) and MRI of paranasal sinus, orbit, skull base and brain were done. The data collected was entered in Microsoft excel and analyzed data was presented in form of frequency and percentage shown by bar chart and pie charts.
Results: The average age of the patients was 50.53 ± 11.280 years. Majority of patients were male (73.3%). Mean duration of onset was 19.28±11.482 days. The most common presenting symptom was headache( 90%). 98.9% (N=178) patients were diabetics, 52.2% patients were known diabetics, newly diagnosed diabetics were 41.7%. 73.90% patients had history of steroid intake. 39 patients were certified dead with overall 21.7% mortality rate.
Conclusions: Increase in mucormycosis in Indian context appears to be an unholy intersection of trinity of COVID-19, Diabetes mellitus and corticosteroid. High suspicion, early diagnosis and rigorous management is the key to favourable prognosis.
References
Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses. 2001;44(7-8):253-60.
Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, Chen SC: The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25:26-34.
Chander J, Kaur M, Singla N. Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi. 2018;4:46.
Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, Kaur A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009;85(1009):573-81.
Hong HL, Lee YM, Kim T, Lee JY, Chung YS, Kim MN, Kim SH, Choi SH, Kim YS, Woo JH, Lee SO. Risk factors for mortality in patients with invasive mucormycosis. Infect Chemother. 2013;45(3):292-8.
Vaezi A, Moazeni M, Rahimi MT, de Hoog S, Badali H. Mucormycosis in Iran: a systematic review. Mycoses. 2016;59(7):402-15.
Palejwala SK, Zangeneh TT, Goldstein SA, Lemole GM. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis. Surg Neurol Int. 2016;7:61.
Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-9.
Kothandaraman N, Rengaraj A, Xue B, Yew WS, Velan SS, Karnani N, Leow MKS. COVID-19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab. 2021;320(1):E139-50.
Perricone C, Bartoloni E, Bursi R, Cafaro G, Guidelli GM, Shoenfeld Y, Gerli R. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res. 2020;68(4):213-24.
Edeas M, Saleh J, Peyssonnaux C. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis? Int J Infect Dis. 2020;97:303-5.
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54(1):S16-22.
Sabirli R, Koseler A, Goren T, Turkcuer I, Kurt O. High GRP78 levels in Covid-19 infection: A case-control study. Life Sci. 2021;265:118781.
